A Study to Assess the Bioavailability of Risankizumab Following Subcutaneous Administration With Prefilled Pen Relative to a Prefilled Syringe in Healthy Adult Participants
This study will assess the pharmacokinetics, relative bioavailability, immunogenicity, safety, and tolerability of risankizumab following subcutaneous (SC) administration with a prefilled pen or a prefilled syringe in healthy adult participants.
Protocol Amendment History
6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-04-21; most recent amendment 2025-12-19.
Status change: Active, Not Recruiting → Completed2025-12-19
Status change: Recruiting → Active, Not Recruiting2025-09-11
Status change: Not Yet Recruiting → Recruiting2025-05-22